Mayo Clinic Q and A: New blood cancer treatment options with chimeric antigen receptor-T cell therapy
Dear Mayo Clinic: My brother was diagnosed with non-Hodgkin lymphoma a few years ago and has had several recurrences. I was reading about something called chimeric antigen receptor-T cell therapy (CAR-T cell therapy) and was wondering how it works and if he might be a candidate for it? Answer: CAR-T cell therapy is a relatively new treatment that [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 30, 2020 Category: Databases & Libraries Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Source: Roche Investor Update - July 14, 2020 Category: Pharmaceuticals Source Type: news

Judge Puts Cloud Over Settlement of Roundup Cancer Claims
An agreement for the weedkiller ’s maker to pay more than $10 billion to end litigation may not get court approval. (Source: NYT Health)
Source: NYT Health - July 7, 2020 Category: Consumer Health News Authors: Patricia Cohen Tags: Hazardous and Toxic Substances Suits and Litigation (Civil) Defoliants and Herbicides Non-Hodgkin ' s Lymphoma Bayer AG Monsanto Company Chhabria, Vince Girdhari Feinberg, Kenneth R Roundup Source Type: news

Highlights in Non-Hodgkin Lymphoma From ASCO 2020 Highlights in Non-Hodgkin Lymphoma From ASCO 2020
Highlights in non-Hodgkin lymphoma from the ASCO 2020 virtual annual meeting include new data on CAR T cells in relapsed/refractory NHL, and Bcl-2 inhibition and chemoimmunotherapy in Richter syndrome.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Blood cancer symptoms: Swelling in this part of the body could be a warning sign
BLOOD CANCER - there are three main types: leukaemia, lymphoma and myeloma. Those with non-Hodgkin lymphoma may experience swelling, but where in the body? (Source: Daily Express - Health)
Source: Daily Express - Health - June 18, 2020 Category: Consumer Health News Source Type: news

Roche presents updated data on novel CD20xCD3 bispecific cancer immunotherapy glofitamab in people with heavily pre-treated non-Hodgkin lymphomas
Basel, 12 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated data on one of its investigational CD20xCD3 T-cell engaging bispecific antibodies, glofitamab (formerly known as CD20-TCB), in people with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). Updated results from the phase I dose-escalation NP30179 study [NCT03075696] of glofitamab, administered via intravenous infusion for a fixed-duration of up to 12 21-day cycles, showed durable complete responses (CRs) in heavily pre-treated patients who had received a median of three prior lines of therapy. These data feature in an oral presentation (...
Source: Roche Investor Update - June 12, 2020 Category: Pharmaceuticals Source Type: news

Caron A. Jacobson, MD, on the Interim Phase II ZUMA-5 Study Safety and Efficacy Findings
The study evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2020 Category: Cancer & Oncology Authors: Caron A. Jacobson, MD Source Type: news

Rituximab + Chemo Ups Survival in Pediatric B-Cell Non-Hodgkin Lymphoma
THURSDAY, June 4, 2020 -- For children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin lymphoma, rituximab added to standard lymphomes malins B (LMB) chemotherapy prolongs event-free survival, according to a study published in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2020 Category: Pharmaceuticals Source Type: news

Phase III results show rituximab excels against pediatric Burkitt lymphoma
(University of Colorado Anschutz Medical Campus) Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news

A new immunotherapeutic agent for children and adolescents with advanced lymphoma
(Comprehensive Cancer Centre Gustave Roussy) The excellent results of the phase III international paediatric study, Inter-B-NHL ritux 2010, have been published in the New England Journal of Medicine. It establishes a new standard treatment with an improved cure rate for children with advanced non-Hodgkin lymphoma, mainly Burkitt lymphoma. It supports the value of an immunotherapeutic agent, which was authorised in March 2020 by the European Commission for the treatment of a rare childhood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2020 Category: Cancer & Oncology Source Type: news

Interim Phase II ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL
Results showed that axicabtagene ciloleucel demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

A new therapeutic target turns the immune system against lymphoma
(Ecole Polytechnique F é d é rale de Lausanne) EPFL scientists have identified a key mechanism that tumor cells use to take advantage of and avoid detection from the immune system. Targeting this mechanism offers a new therapeutic strategy for cancers like Non-Hodgkin lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2020 Category: Cancer & Oncology Source Type: news

NFCR-backed technology receives FDA's assent for lymphoma clinical trials
(National Foundation for Cancer Research) National Foundation for Cancer Research-backed drug and drug delivery technology receives assent from US Food and Drug Administration for T-cell non-Hodgkin's lymphoma clinical trials. The milestone represents another example of promising translational cancer research supported by the organization and its donors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2020 Category: Cancer & Oncology Source Type: news

Caution: Higher Radiation Dose Linked to Worse NHL Outcomes Caution: Higher Radiation Dose Linked to Worse NHL Outcomes
Among patients with non-Hodgkin lymphoma who underwent reduced-intensity conditioning for stem cell transplant, overall survival was lower if they received a higher dose of radiation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 21, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

A randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared...
The objective of this study was to compare the safety and antitumor activity of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma and to investigate the potential benefit of F14512 in P-glycoprotein overexpressing lymphomas. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2020 Category: International Medicine & Public Health Source Type: news

Young Cancer Survivors at Higher Risk for Hospitalization
Risks most elevated for survivors of leukemia, CNS tumors, CRC, non - Hodgkin lymphoma, breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 12, 2020 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Pediatrics, Journal, Source Type: news

Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma
Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease. (Source: CancerNetwork)
Source: CancerNetwork - February 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
(University of Texas M. D. Anderson Cancer Center) According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2020 Category: Cancer & Oncology Source Type: news

FDA clears investigational new drug application for Calibr's 'switchable' CAR-T therapy
(Scripps Research Institute) Calibr, the drug discovery and development division of Scripps Research, today announced that the US Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's 'switchable' CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 3, 2020 Category: International Medicine & Public Health Source Type: news

Nitrite Consumption May Up Risk for Non-Hodgkin Lymphoma
THURSDAY, Jan. 30, 2020 -- Nitrite consumption is associated with an increased risk for non-Hodgkin lymphoma (NHL), according to a meta-analysis published online Jan. 17 in Scientific Reports. Mengxia Yu, from Zhejiang University in Hangzhou, China,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 30, 2020 Category: Pharmaceuticals Source Type: news

Georgia Sterilization Plant Hit with Hefty Fines for EtO Violation
An Atlanta, GA-based medical sterilization plant is learning an expensive lesson after missing a critical deadline related to ethylene oxide (EtO) pollution controls. Sterilization Services of Georgia received a permit on Nov. 7 to use EtO to sterilize medical devices, but the company was supposed to install filters to reduce the gas by Dec. 31. The filters were fully operational as of Jan. 18, according to a Jan. 20 letter, but the Georgia Environmental Protection Department (EPD) fined the company $3,000 for each day beyond the deadline that the filters were not connected. In the letter to the Geo...
Source: MDDI - January 30, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Sterilization Source Type: news

Hashimoto Thyroiditis in Primary Thyroid Non-Hodgkin Lymphoma Hashimoto Thyroiditis in Primary Thyroid Non-Hodgkin Lymphoma
How prevalent is Hashimoto thyroiditis in cases of primary thyroid lymphoma, and what is its etiology? Is Hashimoto thryoiditis a necessary condition for the development of PTL?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 21, 2020 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Report: Roundup cases climb as Bayer edges closer to settlement
The mediator appointed to resolve lawsuits filed against Monsanto Co. involving its Roundup weedkiller said Bayer AG may be weeks away from settling claims that have ballooned to more than 75,000. The plaintiffs in the cases contend that their use of Roundup caused them to develop non-Hodgkin's lymphoma. In an interview with Bloomberg Thursday, Ken Feinberg reiterated his sentiment that he's “cautiously optimistic” about reaching a deal within a month. But he said the caseload — whic h Bayer,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 17, 2020 Category: Biotechnology Authors: Erik Siemers Source Type: news

Using HDAC3 Inhibitors to Reverse CREBBP Mutations in Lymphomas
This research could potentially pave the way for possible immunotherapy approaches for common forms of non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - January 13, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

The Big Number: Why your risks for 7 types of cancer could be reduced with physical activity
Research shows several exercises can be effective against these cancers: breast, colon, endometrial, kidney, liver, multiple myeloma and non-Hodgkin lymphoma. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - January 12, 2020 Category: Consumer Health News Authors: Linda Searing Source Type: news

Exercise may reduce risk for cancer by as much as 25 percent
People who engaged in physical activity as recommended by the NIH were able to reduce their risk for colon and breast cancers, as well as endometrial cancer, kidney cancer, myeloma, liver cancer and non-Hodgkin lymphoma. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 26, 2019 Category: Consumer Health News Source Type: news

Medical News Today: What to know about non-Hodgkin lymphoma
This article looks at their types, symptoms, diagnosis, and treatment. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 11, 2019 Category: Consumer Health News Tags: Lymphoma Source Type: news

Monsanto's former CEO ordered to testify in St. Louis Roundup trial
Former Monsanto Co. Chairman and CEO Hugh Grant has been ordered to testify in persons at a Roundup trial in St. Louis in January. Grant, who led St. Louis-based Monsanto from 2003 until the company was sold to Bayer AG of Germany for $63 billion in 2018, was subpoenaed by lawyers for plaintiff Sharlean Gordon, who contends the Roundup weedkiller caused her non-Hodgkin lymphoma. The trial is scheduled to begin Jan. 27 in St. Louis County Circuit Court. Grant's lawyers have been fighting the subpoena,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 10, 2019 Category: Biotechnology Authors: Greg Edwards Source Type: news

Lenalidomide/Rituximab Combo Improves PFS in Subgroup of Patients with NHL
Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news

No radiation needed for many aggressive non-Hodgkin's lymphoma patients
(SWOG) Most people diagnosed with the most common type of non-Hodgkin's lymphoma can safely skip radiation treatment after a clear PET scan, according to new clinical trial results released today at the 61st American Society of Hematology (ASH) Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 8, 2019 Category: Cancer & Oncology Source Type: news

An Off-the-Shelf Drug to Rival CAR T Cells:'Very Exciting'An Off-the-Shelf Drug to Rival CAR T Cells:'Very Exciting '
A novel bispecific antibody, mosunetuzumab, has shown complete remissions in patients with poor prognosis non-Hodgkin's lymphoma, even those previously treated with CAR T cells.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche announces new data on novel CD20-CD3 bispecific cancer immunotherapies in people with difficult-to-treat lymphomas
Roche today announced new data on two investigational CD20-CD3 T-cell engaging bispecific antibodies, mosunetuzumab and CD20-TCB, in people with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2019 Category: Pharmaceuticals Source Type: news

Lymphoma patients may have new path to remission, even when CAR T therapy fails
(University of Pennsylvania School of Medicine) A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2019 Category: Cancer & Oncology Source Type: news

Married couple and son, 17, ALL battling cancer and have put their family restaurant up for sale
Kathy Desclefs, of Jacksonville, Florida, has been battling non-Hodgkin's lymphoma for five years. This year, her husband Benoit and her son Luke were also diagnosed with cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - December 5, 2019 Category: Consumer Health News Source Type: news

FDA Takes Action to Reduce EtO Use
Shutdowns earlier this year of two facilities that use ethylene oxide (EtO) to sterilize medical devices prompted FDA to monitor for supply shortages in the industry because EtO is such a popular sterilization method for medical devices. This week the agency revealed steps it will take to reduce medtech's reliance on EtO sterilization. EtO is a flammable, colorless gas used to sterilize equipment and plastic devices that cannot be sterilized by steam, such as medical equipment. In fact, about half of all sterilized medical devices undergo sterilization using this gas. Breathi...
Source: MDDI - November 25, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Sterilization Regulatory and Compliance Source Type: news

Radiation From CT Scans Linked to Thyroid Cancer, Leukemia
Elevated risk stronger in women than men; risk for non - Hodgkin lymphoma increased in patients ≤ 45 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 21, 2019 Category: Cancer & Oncology Tags: Endocrinology, Family Medicine, Internal Medicine, Emergency Medicine, Oncology, Radiology, Journal, Source Type: news

B.C. man sues Monsanto, Bayer, alleging Roundup herbicide caused his cancer
Cliff Sissons of Cranbrook, B.C., is suing the makers of the well-used herbicide, alleging exposure over the years caused him to develop non-Hodgkin's lymphoma. The maker of Roundup says the product is safe. (Source: CBC | Health)
Source: CBC | Health - October 18, 2019 Category: Consumer Health News Tags: News/Canada/British Columbia Source Type: news

Recent Research on Diabetes Mellitus, Non-Hodgkin Lymphoma Link
After conflicting opinions over the years, a study published in the journal Hematology explores the association between diabetes mellitus non-hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - October 18, 2019 Category: Cancer & Oncology Authors: Leanne Marcello, MS Source Type: news

Change the'Asymptomatic' Label for Rare Lymphoma Status Change the'Asymptomatic' Label for Rare Lymphoma Status
Patients with a rare form of non-Hodgkin lymphoma who are followed with observation are labeled'asymptomatic,'but they are rarely symptom free.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 10, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Opportunistic Infections, Is Non Hodgkin Lymphoma One of the Risk Factors for Mortality?
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 8, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Itraconazole, an Oral Antifungal Drug, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 4, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

ASTRO: Radiation can nix side effects of T-cell therapy
Patients with non-Hodgkin's lymphoma who received radiation 30 days or less...Read more on AuntMinnie.comRelated Reading: ASTRO: AI predicts side effects from radiation therapy ASTRO: Is hormone therapy after prostate surgery needed? ASTRO: SABR generates immune response to prostate cancer ASTRO: Cervical cancer deaths rise as women's centers close ASTRO: Whole, partial breast RT yield similar cosmetic results (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 20, 2019 Category: Radiology Source Type: news

Medicare Now Covers CAR T-Cell Therapy for Approved Cancers
A promising and expensive type of immunotherapy, called CAR T-cell therapy, is now covered by Medicare. This news may affect mesothelioma patients in the future. Chimeric antigen receptor T-cell, or CAR T-cell, therapy involves the laboratory reprogramming of a patient’s T cells, which are a type of white blood cell responsible for protecting the body against infection and disease. The T cells are genetically modified to better recognize and attack cancer. The U.S. Food and Drug Administration has approved the immunotherapy procedure for non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. It is...
Source: Asbestos and Mesothelioma News - September 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Lymphoma cancer symptoms: A lump in this area of the body could be sign of condition
LYMPHOMA cancer is a type of cancer that develops in the lymphatic system, which is part of the body ’s immune system. More than 13,000 people are diagnosed with non-Hodgkin lymphoma in the UK each year, so what are the signs to look out for? (Source: Daily Express - Health)
Source: Daily Express - Health - September 5, 2019 Category: Consumer Health News Source Type: news

Cancer Victim Says Monsanto Falsely Advertised The Safety Of Its Herbicide Roundup
ST. LOUIS - A cancer victim on Aug. 28 sued Monsanto Co. in Missouri federal court, contending that glyphosate, the active ingredient in the company's herbicide Roundup, caused him to develop non-Hodgkin lymphoma (NHL) and that Monsanto falsely advertised the safety of the product while it had knowledge of glyphosate's carcinogenicity (Kenneth Jilk v. Monsanto Co., No. N/A, E.D. Mo.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - September 3, 2019 Category: Medical Law Source Type: news

Man Says Monsanto's Herbicide Roundup Caused His Cancer
MINNEAPOLIS - A cancer victim on Aug. 28 sued Monsanto Co. in Minnesota federal court, contending that it is responsible for causing his non-Hodgkin lymphoma (NHL) as a result of manufacturing and distributing the herbicide Roundup, which contains the active ingredient glyphosate (Jared Meis v. Monsanto Company, No. 19-2370, D. Minn.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - September 3, 2019 Category: Medical Law Source Type: news

Compassionate Cultivation makes first sale under expanded medical cannabis program
The floodgates are now officially open for Texas' expanded medicinal cannabis program. Cannabis company Compassionate Cultivation announced Aug. 29 its first sale to a terminal cancer patient: Charlotte Friedley of the Austin metro, who is being treated for non-Hodgkin's lymphoma. It is the first time any of the medicinal cannabis companies approved by the state has served a cancer patient, according to the announcement. During its recently completed session, the Texas Legislature passed House… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 29, 2019 Category: Pharmaceuticals Authors: Paul Thompson Source Type: news

Compassionate Cultivation makes first sale under expanded medical cannabis program
The floodgates are now officially open for Texas' expanded medicinal cannabis program. Cannabis company Compassionate Cultivation announced Aug. 29 its first sale to a terminal cancer patient: Charlotte Friedley of the Austin metro, who is being treated for non-Hodgkin's lymphoma. It is the first time any of the medicinal cannabis companies approved by the state has served a cancer patient, according to the announcement. During its recently completed session, the Texas Legislature passed House… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 29, 2019 Category: Biotechnology Authors: Paul Thompson Source Type: news

Amgen and Allergan announce positive top-line results from comparative clinical study of ABP 798, biosimilar candidate to Rituxan ® (rituximab)
Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan® (rituximab), compared to Rituxan in patients with CD20-positive B-cell non-Hodgkin's lymphoma. (Source: World Pharma News)
Source: World Pharma News - August 22, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Translator was diagnosed with stage-four cancer after she dismissed her cough as 'part of winter' 
Magdalena Bujalski, 22, of Winnipeg, Canada, was told her cough was likely just bronchitis, until an X-ray revealed an unusual mass on her right lung. She was diagnosed with Non-Hodgkin Lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - August 5, 2019 Category: Consumer Health News Source Type: news